Literature DB >> 30583130

Stent-Assisted Coil Embolization for a Ruptured Posterior Communicating Artery Pseudoaneurysm After Endoscopic Transsphenoidal Surgery for Pituitary Adenoma.

Yusuke Morinaga1, Kouhei Nii2, Kimiya Sakamoto2, Ritsurou Inoue2, Takafumi Mitsutake2, Hayatsura Hanada2.   

Abstract

BACKGROUND: Intracranial pseudoaneurysm is a rare complication of endoscopic endonasal surgery. Herein, we describe 2-staged stent-assisted coil embolization for posterior communicating artery pseudoaneurysm after endoscopic endonasal surgery for pituitary adenoma. CASE DESCRIPTION: A 68-year-old man had a history of severe adult growth hormone secretion deficiency, requiring growth hormone replacement therapy; secondary adrenocortical hypofunction; hyperthyroidism; hypertension; constipation; glaucoma; and hyperuricemia. Five years ago, after initial endoscopic transsphenoidal surgery for pituitary adenoma, he was hospitalized for reoperation. Posterior communicating artery injury was observed during second endoscopic transsphenoidal surgery, and pressure hemostasis was performed using a hemostatic preparation. Immediately post surgery, a localized subarachnoid hemorrhage was observed. Sudden-onset impaired consciousness and respiratory disturbances ensued on postoperative day 7, and computed tomography of the head was performed. Recurrent subarachnoid hemorrhage was confirmed, and acute hydrocephalus secondary to third ventricular blockage was identified. Cerebral angiography was performed after urgent bilateral cerebral ventricular drainage under general anesthesia. A pseudoaneurysm was identified in the left posterior communicating artery, and coil embolization was performed. Six weeks post surgery, a low-profile visualized intraluminal stent called an LVIS Jr. stent was placed in the posterior communicating artery. Recurrence of the aneurysm was not detected 6 months post surgery. He underwent lumboperitoneal shunting for secondary normal pressure hydrocephalus after dual antiplatelet therapy discontinuation and is being followed up as an outpatient with a modified Rankin scale score of 2 ten months post surgery.
CONCLUSIONS: Two-staged stent-assisted coil embolization using a low-profile visualized intraluminal stent was effective for a posterior communicating artery pseudoaneurysm occurring after posterior communicating artery injury following endoscopic transsphenoidal surgery for follicle-stimulating hormone-producing pituitary adenoma.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endoscopic trans-sphenoidal surgery; Pituitary adenoma; Posterior communicating artery; Pseudoaneurysm; Stent-assisted coil embolization

Mesh:

Year:  2018        PMID: 30583130     DOI: 10.1016/j.wneu.2018.12.047

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  4 in total

Review 1.  Giant Prolactinoma Embedded by Pseudoaneurysm of the Cavernous Carotid Artery Treated with a Tailored Therapeutic Scheme.

Authors:  Valeria Mercuri; Daniele Armocida; Francesco Paglia; Gargiulo Patrizia; Antonio Santoro; Luca D'Angelo
Journal:  J Neurosci Rural Pract       Date:  2022-07-04

2.  Low-profile visualized intraluminal support stent for the endovascular treatment of traumatic intracranial internal carotid artery pseudoaneurysms.

Authors:  Song Tan; Xiaobing Zhou; Yuzhao Lu; Lingfeng Lai; Xiaofei Huang; Bin Li; Yang Wang
Journal:  Neurosurg Rev       Date:  2022-01-24       Impact factor: 3.042

3.  Treatment of an anterior cerebral artery pseudoaneurysm secondary to a transsphenoidal surgery using stent-assisted coiling.

Authors:  Atsushi Ishida; Keizoh Asakuno; Masataka Kato; Hideki Shiramizu; Haruko Yoshimoto; Hikari Sato; Ko Nakase; Masahiro Hirayama; Seigo Matsuo; Shozo Yamada
Journal:  Surg Neurol Int       Date:  2021-01-13

Review 4.  Intracranial Pseudoaneurysms: Evaluation and Management.

Authors:  Yongtao Zheng; Zheng Lu; Jianguo Shen; Feng Xu
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.